Having trouble accessing articles? Reset your cache.

Mogrify raises $16M, outlines plans to advance cell therapy platform

After raising $16 million in the first close of a series A round, Mogrify unveiled more of its cell therapy pipeline and laid out goals to enhance its cell reprogramming platform. Existing investor Ahren Innovation Capital led the round.

While Cambridge, U.K.-based Mogrify Ltd. expects this initial close to provide at least two years of runway, it’s

Read the full 562 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers